arrow
F

France Mentré

INSERM
H指数:72
被引数:2.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Soluble ST2 dynamics are associated with delayed hospital discharge in COVID-19 patients: a joint-modeling analysis of the DisCoVeRy trial’s longitudinal data.

可溶性ST2动力学与COVID-19患者延迟出院相关:DisCoVeRy试验纵向数据的联合建模分析

2026-08-070
PRE
High Nasopharyngeal SARS-CoV-2 Load and Delayed Clearance in Hospitalized Patients With Blood Autoantibodies Neutralizing Type I Interferons

住院患者中血液自身抗体中和I型干扰素导致鼻咽部SARS-CoV-2病毒载量高且清除延迟

2026-01-010
PRE
Hydroxychloroquine does not affect endotheliopathy or coagulopathy biomarkers in COVID-19: longitudinal results from the DisCoVeRy randomized trial

羟氯喹对COVID-19的血管内皮功能障碍或凝血功能障碍生物标志物无影响:DisCoVeRy随机试验的纵向结果

2025-12-070
OAAI
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM plus approaches - further results based on more conventional practices

协变量模型构建方法对其临床相关性评估的影响:全模型、逐步协变量模型(SCM)和SCM加法方法的比较——基于更常规实践的进一步结果

2025-09-271
PRE
A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders

基于药代动力学信息指导的试验模拟框架,用于优化罕见神经系统疾病疾病修饰性治疗的研究设计

2025-08-050
OAAI
Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials

Janus kinase抑制剂在因COVID-19住院的成人中的效果:一项随机临床试验的系统评价和个体参与者数据荟萃分析

2025-05-130
OA
Clinical Characterization and Outcomes of Human Clade IIb Mpox Virus Disease: A European Multicenter Mpox Observational Cohort Study (MOSAIC)

人类进化枝IIb Mpox病毒疾病的临床特征和结果: 一项欧洲多中心Mpox观察性队列研究 (MOSAIC)

2025-01-030
OAAI
Cardiac Adverse Events and Remdesivir in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19): A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial
2024-03-295
OAAI
Perturbation and resilience of the gut microbiome up to 3 months after β-lactams exposure in healthy volunteers suggest an important role of microbial β-lactamases
2024-03-122
OAAI
Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trial
2024-03-014
OA